

1 **A machine-learning model to harmonize brain volumetric data for quantitative neuro-radiological**
2 **assessment of Alzheimer’s disease**

3 **Authors:**

4 Damiano Archetti^{1,*}, Vikram Venkatraghavan^{2,3,*}, Béla Weiss^{4,5}, Pierrick Bourgeat⁶, Tibor Auer^{4,7},
5 Zoltán Vidnyánszky⁴, Stanley Durrleman⁸, Wiesje M. van der Flier^{2,3,9}, Frederik Barkhof^{10,11,12}, Daniel
6 C. Alexander¹², Andre Altmann¹², Alberto Redolfi¹, Betty M. Tijms^{2,3}, Neil P. Oxtoby¹², for the
7 Australian Imaging Biomarkers and Lifestyle Study[†], for the Alzheimer’s Disease Neuroimaging
8 Initiative[‡], and for the E-DADS Consortium

9 1 Laboratory of Neuroinformatics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia,
10 Italy;

11 2 Alzheimer Center Amsterdam, Neurology, Vrije Universiteit, Amsterdam UMC, location VUmc,
12 Amsterdam, the Netherlands;

13 3. Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands;

14 4 Brain Imaging Centre, Research Centre for Natural Sciences, Budapest, Hungary;

15 5 Biomatics and Applied Artificial Intelligence Institute, John von Neumann Faculty of
16 Informatics, Óbuda University, Budapest, Hungary

17 6 The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, Queensland,
18 Australia;

19 7 School of Psychology, University of Surrey, Guildford, United Kingdom;

20 8 Sorbonne Université, Institut du Cerveau - Paris Brain Institute – ICM, CNRS, Inria, Inserm, AP-HP,
21 Hôpital Pitié-Salpêtrière, Paris, France;

22 9 Department of Epidemiology and Data Science, Vrije Universiteit, Amsterdam UMC, location
23 VUmc, the Netherlands;

24 10 Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, the
25 Netherlands;

26 11 Queen Square Institute of Neurology, University College London, United Kingdom;

27 12 UCL Centre for Medical Image Computing, Department of Medical Physics and Biomedical
28 Engineering and Department of Computer Science, University College London, United Kingdom;

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 *Indicates shared first co-authorship, with the first co-authors being listed alphabetically.

30 † Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers
31 and Lifestyle (AIBL) Study. Unless named, the AIBL researchers contributed data but did not
32 participate in analysis or writing of this report. AIBL researchers are listed at <https://aibl.org.au>

33 ‡ Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging
34 Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed
35 to the design and implementation of ADNI and/or provided data but did not participate in analysis or
36 writing of this report. A complete listing of ADNI investigators can be found at:

37 http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

38 **Corresponding author:**

39 Damiano Archetti (OrCID: 0000-0003-0818-7685)

40 E-mail: darchetti@fatebenefratelli.eu

41 Phone: +39 0303501502

42 Address: Via Pilastroni 4, Brescia, 25125, Italy

43 **Contributors' contacts**

44 Vikram Venkatraghavan (OrCID: 0000-0001-9759-0462): v.venkatraghavan@amsterdamumc.nl

45 Béla Weiss (OrCID: 0000-0003-1031-0283): weiss.bela@ttk.hu

46 Pierrick Bourgeat (OrCID: 0000-0002-2605-4766): pierrick.bourgeat@csiro.au

47 Tibor Auer (OrCID: 0000-0001-5153-1424): t.auer@surrey.ac.uk

48 Zoltán Vidnyánszky (OrCID: 0000-0003-3914-3087): vidnyanszky.zoltan@ttk.hu

49 Stanley Durrleman (OrCID: 0000-0002-9450-6920): stanley.durrleman@inria.fr

50 Wiesje M. van der Flier (OrCID: 0000-0001-8766-6224): wm.vdflier@amsterdamumc.nl

51 Frederik Barkhof (OrCID: 0000-0003-3543-3706): f.barkhof@amsterdamumc.nl

52 Daniel C Alexander (OrCID: 0000-0003-2439-350X): d.alexander@ucl.ac.uk

53 Andre Altmann (OrCID: 0000-0002-9265-2393): a.altmann@ucl.ac.uk

54 Alberto Redolfi (OrCID: 0000-0002-4145-9059): aredolfi@fatebenefratelli.eu

55 Betty M. Tijms (OrCID: 0000-0002-2612-1797): b.tijms@amsterdamumc.nl

56 Neil P Oxtoby (OrcID: 0000-0003-0203-3909): n.oxtoby@ucl.ac.uk

57 **Abstract:**

58 **Background:** Structural MRI plays a pivotal role in the radiological workup for assessing
59 neurodegeneration. Scanner-related differences hinder quantitative neuroradiological assessment of
60 Alzheimer’s disease (QNAD). This study aims to train a machine-learning model to harmonize brain
61 volumetric data of patients not encountered during model training.

62 **Method:** Neuroharmony is a recently developed method that uses image quality metrics (IQM) as
63 predictors to remove scanner-related effects in brain-volumetric data using random forest regression.
64 To account for the interactions between AD-pathology and IQM during harmonization, we developed
65 a multi-class extension of Neuroharmony. We performed cross-validation experiments to benchmark
66 performance against existing approaches using data from 20,864 participants comprising cognitively
67 unimpaired (CU) and impaired (CI) individuals, spanning 11 cohorts and 43 scanners. Evaluation
68 metrics assessed ability to remove scanner-related variations in brain volumes (biomarker
69 concordance), while retaining the ability to delineate different diagnostic groups (preserving disease-
70 related signal).

71 **Results:** For each strategy, biomarker concordances between scanners were significantly better ($p <$
72 10^{-6}) compared to pre-harmonized data. The proposed multi-class model achieved significantly
73 higher concordance than the Neuroharmony model trained on CU individuals (CI: $p < 10^{-6}$, CU: $p =$
74 0.02) and preserved disease-related signal better than the Neuroharmony model trained on all
75 individuals without our proposed extension ($\Delta\text{AUC} = -0.09$). The biomarker concordance was better
76 in scanners seen during training (concordance $> 97\%$) than unseen (concordance $< 79\%$),
77 independent of cognitive status.

78 **Conclusion:** In a large-scale multi-center dataset, our proposed multi-class Neuroharmony model
79 outperformed other strategies available for harmonizing brain-volumetric data in a clinical setting.
80 This paves the way for enabling QNAD in the future.

81 **1 Introduction**

82 Structural MRI such as T1-weighted (T1w) sequences are routinely acquired in memory clinics for
83 diagnosing Alzheimer's disease (AD)¹, clinical phenotyping², and for differentiating AD from other
84 types of dementias³. In current clinical practice, radiologists primarily assess global and regional
85 atrophy through visual examination of MRI. However, visual examinations are subjective and prone
86 to intra-rater and inter-rater variability. Quantitative imaging biomarkers such as brain volumetric
87 data are becoming increasingly popular because of their potential to improve diagnostic confidence⁴.
88 Quantitative imaging biomarkers can be used for objective assessment in the radiological workflow
89 either by using automated digital tools based on normative modelling³ or using latest advances in
90 artificial intelligence such as brain-age estimation⁵, or data-driven subtyping⁶.

91 However, differences in MRI acquisition protocols and scanners affect consistency and reproducibility
92 of brain volumetry⁷ and are a major impediment for the clinical translation to automated tools. To
93 tackle this problem, many harmonization tools have emerged in recent years⁸. Such algorithms can
94 either harmonize original scans⁹ or derivatives extracted from the scans¹⁰. Some of these algorithms
95 have been shown to harmonize patient data affected by a neurodegenerative disease^{11,12}, while
96 preserving disease-related signature. However, such harmonization techniques typically work only for
97 the scanner models they have been trained on, and, in some instances require the same subjects to
98 be scanned with multiple different scanners¹³. Harmonizing volumetric data from MRI scanners not
99 encountered during initial model training needs additional training with a substantial number of
100 images from these scanners¹⁴. This poses a challenge for the deployment of such methods for clinical
101 use.

102 Neuroharmony¹⁵ is a recently developed harmonization approach that can harmonize volumetric data
103 from new and unseen MRI scanners. It works under the assumption that the corrections needed to
104 harmonize data from multiple scanners can be predicted from image quality metrics (IQM) computed
105 from the scans. While the original experiments indicate that harmonization works for healthy controls,
106 harmonizing data from patients with neurodegenerative diseases remains an open problem. This is
107 because disease pathology in patients may affect the IQM, and such effects remain unaccounted for
108 in a Neuroharmony model trained on healthy controls.

109 In this paper we propose an extension of Neuroharmony to account for interaction between disease
110 pathology and IQM to remove scanner-related effects (multi-class model of Neuroharmony). We
111 systematically compare the performances of the proposed multi-class model in harmonizing data with
112 two other approaches: the original Neuroharmony model trained only on cognitively unimpaired (CU)
113 individuals (normative model of Neuroharmony) and the original Neuroharmony model trained on

114 cognitively unimpaired as well as cognitively impaired (CI) individuals without our proposed multi-
115 class extension (inclusive model of Neuroharmony). We used data from 11 cohorts across three
116 continents for evaluating these approaches. Lastly, we identify key challenges for clinical
117 implementation of the best multicentric harmonization strategy identified in our experiments for
118 enabling quantitative neuroradiological assessment of Alzheimer’s disease (QNAD).

119 **2 Materials and Methods**

120 2.1 Participants and scanner characteristics

121 T1w MRI data of healthy controls (CN), participants with subjective cognitive decline (SCD), mild
122 cognitive impairment (MCI), and Alzheimer’s disease (AD) from 11 data cohorts were included in our
123 analysis. The cohorts considered for this study were: Amsterdam Dementia Cohort (ADC)¹⁶,
124 Alzheimer’s Disease Neuroimaging Initiative (ADNI)¹⁷, Australian Imaging, Biomarker & Lifestyle
125 Flagship Study of Ageing (AIBL)¹⁸, Alzheimer’s Repository Without Borders (ARWiBo)¹⁹, European DTI
126 Study on Dementia (EDSD)²⁰, Hungarian Longitudinal Study of Healthy Brain Aging (HuBA)²¹, Italian
127 Alzheimer’s Disease Neuroimaging Initiative (I-ADNI)²², National Alzheimer’s Coordination Center
128 (NACC)²³, Open Access Series of Imaging Studies (OASIS, versions 1&2)²⁴, European Alzheimer’s
129 Disease Neuroimaging Initiative (also known as PharmaCOG)²⁵, and UK Bio-bank (UKBB)²⁶. Detailed
130 information about each cohort is summarized in Supplementary Table 1.

131 Minimum inclusion criteria included the availability of a T1w MRI scan along with age, sex, scanner
132 information, and a clinical diagnosis of either CN, SCD, MCI or AD. All datasets were organized
133 according to the BIDS standard²⁷ to ensure inter-operability and data anonymization. An overview of
134 the scanners used in this study is shown in Table 1.

135 2.2 Image processing

136 Cortical reconstruction and volumetric segmentation were performed with the cross-sectional
137 pipeline of FreeSurfer v7.1.1²⁸ in order to extract volumes of 68 cortical regions in the Desikan-Killiany
138 atlas, 14 subcortical brain regions, as well as total CSF volume, total gray matter volume and total
139 brain volume with and without ventricles. All features derived from FreeSurfer are listed in
140 Supplementary Figure 1. IQM were estimated using MRIQC v0.16.1²⁹. Automatic quality control of the
141 FreeSurfer segmentations was performed using the Euler number, where outliers defined as 1.5×IQR
142 (inter-quartile range) below the first quartile and 1.5×IQR above the third quartile³⁰ per scanner were
143 excluded from our experiments.

144 In order to ensure reproducibility of our results across different computing environments³¹, Docker
145 containers for both FreeSurfer (<https://github.com/E-DADS/freesurfer>) and MRIQC
146 (<https://github.com/E-DADS/mriqc>) have been made available online.

147 2.3 Multi-class Neuroharmony model

148 The volumetric data from all individuals in the training set were harmonized using ComBat
149 harmonization¹⁰ with empirical Bayes optimization, for removing scanner related batch effects while

150 preserving the effects of age, sex, and cognitive status. The cognitive status was dichotomized based
151 on the clinical diagnosis as either CU (CN and SCD) or CI (MCI and AD). Subsequently, a random forest
152 regressor was trained with MRIQC-derived IQM to predict the corrections needed to harmonize the
153 volumes as predicted by ComBat. To ensure the regressor learns to predict the corrections needed to
154 harmonize accurately in the presence of AD pathology, we used synthetic minority oversampling
155 technique (SMOTE) for data augmentation³² before training the random forest regressor. This ensured
156 that IQM values with and without neurodegeneration were equally distributed by removing data
157 imbalance between CI and CU individuals. The use of dichotomized cognitive status instead of clinical
158 diagnosis ensured that in the test phase, a full clinical diagnosis is not required as an input to predict
159 the harmonized volumes. The hyperparameters for the random forest regressor were chosen to be
160 the same as the ones used in the original Neuroharmony paper.¹⁵

161 2.4 Model comparisons

162 The performance of the proposed multi-class extension to Neuroharmony was compared with two
163 other machine-learning based harmonization strategies that are generalizable to external datasets:

164 *2.4.1 Normative model:* In the training phase, volumetric data from only the CU individuals were
165 harmonized using ComBat harmonization using the aforementioned strategy, while preserving the
166 effects of age and sex. Subsequently, a random forest regressor was trained to predict the corrections
167 needed to harmonize the volumes as predicted by ComBat using MRIQC-derived IQM.

168 *2.4.2 Inclusive model:* The training strategy remained the same as for the normative model, but
169 volumetric data of both CU and CI individuals were used for training.

170 2.5 Measures for model evaluations

171 We use two evaluation metrics to assess the ability of the harmonization strategies to remove
172 scanner-related variations in brain-volumetric data between each pair of scanners (biomarker
173 concordance), while retaining the ability to delineate diagnostic groups (preserving disease-related
174 signal).

175 Firstly, to assess if the volumetric data are harmonized, we compared the distributions of each
176 volumetric measure for each pair of scanners. This was done independently within each diagnostic
177 group, and after correcting for the confounding effects of age and sex by regressing out their effects
178 estimated in CU individuals. The Kolmogorov-Smirnov (KS) test was used for comparing these
179 distributions with the null hypothesis that the distributions between any two pair of scanners were
180 the same. For statistical validity we excluded scanners with fewer than 10 participants of the same
181 diagnostic group from this evaluation. A measure for evaluating harmonization was defined as the

182 percentage of such comparisons across brain regions for each scanner pair, where distributions were
183 *not* statistically different from each other ($p \geq 0.05$) after correcting for multiple testing via false
184 discovery rate (FDR). To provide a reference measure for biomarker concordance, we also computed
185 this measure in the non-harmonized data.

186 Secondly, to assess if disease-related signal was preserved in the volumetric measures, we used area
187 under the receiver operating characteristic (ROC) curve (AUC) as an auxiliary evaluation measure. The
188 ROC curve for distinguishing CN participants from AD patients was computed independently for each
189 volumetric measure. A reference measure for AUC was also computed for the non-harmonized
190 dataset.

191 2.6 Cross-validation experiments

192 We performed two experiments in a cross-validation framework. Experiment 1 assessed concordance
193 of the three harmonization strategies, by performing cross-validation at the scanner-level. Experiment
194 2 performed cross-validation at the participant level, using the best-performing scanner-level
195 harmonization models.

196 Experiment 1: To investigate the generalizability of the model to unseen scanners (not included in the
197 training set), we performed 5-fold cross-validation across the 43 available scanners, where in each
198 fold 80% of the scanners were used for training the models, and the remaining 20% of the scanners
199 were used for evaluation. In this experiment, to evaluate the bias introduced by using single-scanner
200 data from the large UKBB cohort, we repeated this experiment for increasing portions of UKBB
201 participants such that when the UKBB data is included in the training data the proportions included
202 were: 10%; 33%; 67%; 100%. However, when UKBB cohort data is used in the test set, we always used
203 100% of the cohort. The non-parametric McNemar Chi-square test was used to compare accuracies
204 across harmonization strategies.

205 Experiment 2: In this experimental setup, the test set consisted of participants from the scanners
206 which were also present in the training set. We selected the two best performing models from
207 Experiment 1 and performed a stratified 5-fold cross-validation across participants, stratified based
208 on the dichotomized cognitive status. For this, the proportion of the UKBB participants included was
209 also decided based on Experiment 1. To provide a reference measure, we compared the accuracies
210 obtained with the corresponding accuracies obtained in Experiment 1.

211 **3 Results**

212 3.1 Participants

213 Table 2 shows descriptive statistics for the combined study sample used in our experiments, which
214 consisted of QC-passed volumetric data from 20,864 participants (53.3% female) from 43 scanners
215 across 11 cohorts. Figure 1 shows age distributions by scanner and cognitive group.

216 3.2 Model evaluation

217 Figure 2 shows the first result of Experiment 1: biomarker concordance under cross-validation,
218 independently for each diagnostic group and with increasing proportions of the UKBB dataset.
219 Reference concordance for non-harmonized dataset are also shown for each diagnostic group for
220 comparison. As expected, concordance for each harmonization strategy were significantly higher than
221 the non-harmonized data for all the diagnostic groups ($p < 10^{-6}$). The use of the inclusive and multi-
222 class models significantly improved the concordance with respect to the normative model for the
223 diagnostic categories of MCI and AD ($p < 10^{-6}$). For diagnostic groups of CN and SCD, the
224 concordance of the multi-class model was significantly higher than the normative model when the
225 proportion of UKBB subjects included was 100% ($p_{CN} = 0.01, p_{SCD} = 0.02$). The inclusive model's
226 concordance for CN and SCD subjects was statistically similar to that of the normative model ($p >$
227 0.05).

228 Figure 3 shows the second result of Experiment 1: CN vs AD AUC computed independently for each
229 brain regional volume in the test set. Removing scanner-related differences decreased AUC for all
230 harmonization approaches, potentially due to the imbalance in the number of CN and AD participants
231 in the different scanners. The AUCs of the normative model and multi-class model are slightly lower
232 than non-harmonized volumes ($\Delta AUC = -0.01$, paired t-test $p = 10^{-5}$). However, the multi-class
233 model significantly outperformed the inclusive model ($\Delta AUC = -0.09$, paired t-test $p < 10^{-10}$),
234 indicating relative loss of disease related signal when using the inclusive model harmonization
235 strategy.

236 3.3 Harmonization in seen vs unseen MRI scanners

237 Figure 4 shows the results of Experiment 2: biomarker concordance as a function of scanners seen vs
238 unseen scanners during model training, for the normative model and the multi-class model.
239 Supplementary Figure 1 shows the same for each brain volume individually. Biomarker concordance
240 of the multi-class model was significantly higher than the normative model for unseen scanners, based
241 on McNemar test for all diagnostic categories ($p_{CN} = 0.01, p_{SCD} = 0.02, p_{MCI} < 10^{-6}, p_{AD} <$
242 10^{-6}). For seen scanners, the multi-class model harmonization strategy significantly outperformed

243 the normative model for the diagnostic groups of CN, MCI, and AD ($p_{CN} < 10^{-6}, p_{MCI} < 10^{-6}, p_{AD} <$
244 10^{-6}), but significantly underperformed for SCD ($p_{SCD} = 0.02$). Harmonization accuracy using the
245 multi-class model in a seen scanner (accuracy > 97%) was better for all diagnostic groups than in
246 unseen scanners (accuracy < 79%).

247 **4 Discussion**

248 We introduced a novel extension to the Neuroharmony harmonization model to train a generalizable
249 machine learning model for harmonizing multicentric brain-volumetric data for quantitative neuro-
250 radiological assessment of Alzheimer's disease. The data for these evaluation experiments were
251 derived from T1w MRIs acquired with 43 different scanners from 20,864 participants spanning 11
252 cohorts. The newly introduced multi-class model would be helpful in harmonizing volumetric data
253 while using automated methods in clinics and research where there could be data from new scanners
254 not included in training. The trained model has been made openly available at
255 https://www.neugrid2.eu/index.php/edads_harmonization/ while the code to train the model has
256 been made available in: <https://github.com/e-dads/Multiclass-Neuroharmony/>.

257 Our experiments showed that the multi-class model, that accounts for the interaction between
258 disease pathology and image quality metrics to remove scanner-related effects, significantly improved
259 harmonization accuracy for patients in unseen scanners, as compared to normative modelling. For
260 seen scanners, it improved the harmonization accuracy for all diagnostic groups except SCD,
261 potentially due to the low sample size of the SCD group (n=1,376). Additionally, we showed that the
262 multi-class model of Neuroharmony preserves disease-related signature during harmonization.

263 Harmonization of biomarker data from unseen scanners remains a challenge: biomarker concordance
264 for both normative and multi-class models in unseen scanners was lower than obtained for seen
265 scanners. While this leaves scope for further methodological improvements to harmonization
266 strategies for unseen scanners, it would also be useful to investigate if the achieved harmonization
267 performance is sufficient for the generalizability of machine learning approaches such as classification,
268 subtyping³³, and brain aging.

269 The different number of participants used to train the respective models could potentially bias the
270 results against the model which uses a smaller dataset for training (normative model). However, we
271 think this setting is a realistic and fair comparison, because normative modelling always discards data
272 from CI individuals. Through our modifications to the Neuroharmony model, we provided a way to
273 include both CI and CU individuals in the training data, which our experiments show improves
274 harmonization in both seen and unseen scanners while preserving disease-related signature.

275 The harmonization performance obtained with the normative model in our experiments was lower
276 than reported in the original Neuroharmony paper¹⁵. We think this is due to removal of sex and age
277 variability in the original Neuroharmony method. We preserved these effects, retaining this biological
278 variability, which we would argue is important for both research studies and future clinical
279 implementation.

280 Some limitations of the original Neuroharmony model¹⁵ also apply to this work as well. The
281 harmonization performance for an individual in the test-set depends on the contrast-to-noise ratio in
282 the T1w MRI and the pipeline cannot guarantee effective harmonization if the ratio is outside the
283 range seen in our training data, and might lead to incorrect harmonization. Secondly, the
284 harmonization performance based on biomarker concordance across scanner-pairs is a surrogate
285 measure to measure consistency in the absence of a ground-truth. To overcome this limitation, it
286 would be useful to measure the harmonization performance for participants scanned with multiple
287 scanners, in the future.

288 An important limitation of this study, as with most research studies in this field, is that the imaging
289 data used predominantly came from the developed Western countries of the EU, US, UK, and
290 Australia. A more generalizable and inclusive machine learning model for harmonization would
291 require data from nations in South-America, Asia, and Africa. This would include low field-strength
292 scanners that are predominantly used in these regions, as well as more diverse biological variation in
293 the training data. Large global consortia such as the UNITED consortium³⁴ could potentially help in
294 getting access to such diverse neuroimaging data. Further developing Neuroharmony for distributed
295 or federated learning for harmonizing imaging data can also facilitate data inclusion from under-
296 represented countries.

297 Challenges in the clinical implementation of the harmonization strategy: while the multi-class model
298 outperformed the normative model in terms of harmonization accuracy, the implementation of the
299 model in memory clinics might require additional work to include cognitive status of a patient during
300 regular radiological workup. Machine learning models could potentially be used to overcome this
301 limitation as it has been shown in recent studies that classifying CI from CN/SCD can be done with high
302 accuracy using MRI³⁵. To avoid a circular dependency between the two tasks, we think that developing
303 multi-task machine learning models to jointly harmonize and predict cognitive status is an important
304 avenue of future work.

305 While the current work was focused on the AD spectrum, we expect that our new method will be
306 valuable for impaired cognition in general (e.g.: vascular dementia, frontotemporal dementia,
307 dementia with Lewy bodies). Future work validating harmonization approaches for patients with other
308 types of dementia is crucial for eventual clinical implementation.

309 In summary, we have generalized the Neuroharmony model to harmonize imaging biomarker data
310 from multisite studies while retaining disease signal that could otherwise be removed by the
311 harmonization procedure. Demonstrating on brain MRI biomarker data from the Alzheimer's disease
312 spectrum, our new method outperforms others on both seen and unseen scanners, making it more

- 313 suitable for clinical applications related to cognitive decline, such as memory clinics and clinical trials
- 314 of new interventions for neurodegenerative diseases.

315 **Funding**

316 This study was supported by the Early Detection of Alzheimer's Disease Subtypes (E-DADS) project, an
317 EU Joint Programme — Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). The
318 project is supported under the aegis of JPND through the following funding organizations: United
319 Kingdom, Medical Research Council (MR/T046422/1); Netherlands, ZonMW (733051106); France,
320 Agence Nationale de la Recherche (ANR-19-JPW2-000); Italy, Italian Ministry of Health (MoH);
321 Australia, National Health & Medical Research Council (1191535); Hungary, National Research,
322 Development and Innovation Office (2019-2.1.7-ERA-NET-2020-00008).

323 This work used the Dutch national e-infrastructure with the support of the SURF Cooperative using
324 grant no. EINF-5353. F.B. is supported by the NIHR Biomedical Research Centre at UCLH. B.W. and Z.V.
325 were supported by Project no. RRF-2.3.1-21-2022-00015, which has been implemented with the
326 support provided by the European Union. B.W. was supported by the Consolidator Researcher
327 program of the Óbuda University.

328 N.P.O. is supported by a UKRI Future Leaders Fellowship (UK Medical Research Council
329 MR/S03546X/1).

330 **Acknowledgments**

331 The authors would like to thank the developers of the original Neuroharmony algorithm for making
332 the code available, and all the research participants and their families for donating their data for
333 scientific research.

334 Data collection and sharing for ADNI was funded by the Alzheimer's Disease Neuroimaging Initiative
335 (ADNI) (National Institutes of Health Grant [U01 AG024904](#)) and DOD ADNI (Department of Defense
336 award number [W81XWH-12-2-0012](#)). ADNI is funded by the National Institute on Aging, the National
337 Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the
338 following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech;
339 BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan
340 Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated
341 company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy
342 Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.;
343 Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack
344 Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda
345 Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is
346 providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by

347 the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the
348 Northern California Institute for Research and Education , and the study is coordinated by the
349 Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are
350 disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

351 The AIBL study (<https://aibl.org.au>) is a consortium between Austin Health, CSIRO, Edith Cowan
352 University, the Florey Institute (The University of Melbourne), and the National Ageing Research
353 Institute. The study has received partial financial support from the Alzheimer’s Association (US), the
354 Alzheimer’s Drug Discovery Foundation, an Anonymous foundation, the Science and Industry
355 Endowment Fund, the Dementia Collaborative Research Centres, the Victorian Government’s
356 Operational Infrastructure Support program, the Australian Alzheimer’s Research Foundation, the
357 National Health and Medical Research Council (NHMRC), and The Yulgilbar Foundation. Numerous
358 commercial interactions have supported data collection and analyses. In-kind support has also been
359 provided by Sir Charles Gairdner Hospital, Cogstate Ltd, Hollywood Private Hospital, The University of
360 Melbourne, and St Vincent’s Hospital. The AIBL team wishes to thank all clinicians who referred
361 patients with AD and/or MCI to the study. We also thank all those who took part as subjects in the
362 study for their commitment and dedication to helping advance research into the early detection and
363 causation of AD. We thank all the investigators within the AIBL who contributed to the design and
364 implementation of the resource and/or provided data but did not actively participate in the
365 development, analysis, interpretation or writing of this current study.

366 The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the
367 NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD),
368 P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30
369 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert,
370 PhD), P30 AG066444 (PI John Morris, MD), P30 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI
371 Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD),
372 P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI
373 David Bennett, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30
374 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI
375 Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD),
376 P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973
377 (PI Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI Stephen
378 Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne
379 Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20
380 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary

381 Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD),
382 P30 AG072959 (PI James Leverenz, MD).

383 **Conflicts of interest**

384 F.B. is on the steering committee or Data Safety Monitoring Board member for Biogen, Merck,
385 ATRI/ACTC and Prothena. F.B. has been a consultant for Roche, Celltrion, Rewind Therapeutics, Merck,
386 IXICO, Jansen, Combinostics and has research agreements with Merck, Biogen, GE Healthcare, Roche.
387 F.B. and D.C.A. are co-founders and shareholders of Queen Square Analytics Ltd. N.P.O. is a consultant
388 for Queen Square Analytics Ltd.

389 **Data and code availability**

390 ADC data can be made available to academic researchers upon reasonable request;

391 ADNI and AIBL data are stored at the Laboratory of Neuroimaging at the University of Southern
392 California and are available to the general scientific community for download:

393 <http://adni.loni.usc.edu>;

394 ArWiBO, ESDS, I-ADNI, OASIS and PharmaCog data are available for all researchers on the NeuGRID2
395 platform: <https://www.neugrid2.eu/> (<https://doi.org/10.17616/R31N1E>);

396 HuBA data can be made available upon reasonable request;

397 NACC data is available through the National Alzheimer's Coordinating Center platform:

398 <https://naccdata.org/>;

399 UKBB data is available at the UK Biobank platform: <https://www.ukbiobank.ac.uk/>;

400 Docker containers for FreeSurfer and MriQC are available on the E-DADS GitHub:

401 <https://github.com/E-DADS/freesurfer>, <https://github.com/E-DADS/mriqc>;

402 Multi-class Neuroharmony harmonization algorithm is available on GitHub:

403 <https://github.com/88vikram/Multiclass-Neuroharmony>;

404 Harmonization model files are available for all researchers on the NeuGRID2 platform:

405 https://www.neugrid2.eu/index.php/edads_harmonization.

406

407 References

- 408 1. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. *Cold Spring*
409 *Harb Perspect Med*. Apr 2012;2(4):a006213. doi:10.1101/cshperspect.a006213
- 410 2. Ossenkoppele R, Cohn-Sheehy BI, La Joie R, et al. Atrophy patterns in early clinical stages
411 across distinct phenotypes of Alzheimer's disease. *Hum Brain Mapp*. Nov 2015;36(11):4421-37.
412 doi:10.1002/hbm.22927
- 413 3. Hedderich DM, Dieckmeyer M, Andrisan T, et al. Normative brain volume reports may
414 improve differential diagnosis of dementing neurodegenerative diseases in clinical practice. *Eur*
415 *Radiol*. May 2020;30(5):2821-2829. doi:10.1007/s00330-019-06602-0
- 416 4. Goodkin O, Pemberton H, Vos SB, et al. The quantitative neuroradiology initiative
417 framework: application to dementia. *Br J Radiol*. Sep 2019;92(1101):20190365.
418 doi:10.1259/bjr.20190365
- 419 5. Wang J, Knol MJ, Tiulpin A, et al. Gray Matter Age Prediction as a Biomarker for Risk of
420 Dementia. *Proc Natl Acad Sci U S A*. Oct 15 2019;116(42):21213-21218.
421 doi:10.1073/pnas.1902376116
- 422 6. Young AL, Marinescu RV, Oxtoby NP, et al. Uncovering the heterogeneity and temporal
423 complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nat Commun*. Oct 15
424 2018;9(1):4273. doi:10.1038/s41467-018-05892-0
- 425 7. Liu S, Hou B, Zhang Y, Lin T, Fan X, You H, Feng F. Inter-scanner reproducibility of brain
426 volumetry: influence of automated brain segmentation software. *BMC Neurosci*. Sep 4
427 2020;21(1):35. doi:10.1186/s12868-020-00585-1
- 428 8. Gebre RK, Senjem ML, Raghavan S, et al. Cross-scanner harmonization methods for
429 structural MRI may need further work: A comparison study. *Neuroimage*. Apr 1 2023;269:119912.
430 doi:10.1016/j.neuroimage.2023.119912
- 431 9. Dewey BE, Zhao C, Reinhold JC, et al. DeepHarmony: A deep learning approach to contrast
432 harmonization across scanner changes. *Magn Reson Imaging*. Dec 2019;64:160-170.
433 doi:10.1016/j.mri.2019.05.041
- 434 10. Fortin JP, Cullen N, Sheline YI, et al. Harmonization of cortical thickness measurements
435 across scanners and sites. *Neuroimage*. Feb 15 2018;167:104-120.
436 doi:10.1016/j.neuroimage.2017.11.024
- 437 11. Pagani E, Storelli L, Pantano P, et al. Multicenter data harmonization for regional brain
438 atrophy and application in multiple sclerosis. *J Neurol*. Jan 2023;270(1):446-459.
439 doi:10.1007/s00415-022-11387-2
- 440 12. Zhou HH, Singh V, Johnson SC, Wahba G, Alzheimer's Disease Neuroimaging I. Statistical
441 tests and identifiability conditions for pooling and analyzing multisite datasets. *Proc Natl Acad Sci U S*
442 *A*. Feb 13 2018;115(7):1481-1486. doi:10.1073/pnas.1719747115
- 443 13. Potvin O, Chouinard I, Dieumegarde L, et al. The Canadian Dementia Imaging Protocol:
444 Harmonization validity for morphometry measurements. *Neuroimage Clin*. 2019;24:101943.
445 doi:10.1016/j.nicl.2019.101943
- 446 14. Kia SM, Huijsdens H, Rutherford S, et al. Closing the life-cycle of normative modeling using
447 federated hierarchical Bayesian regression. *PLoS One*. 2022;17(12):e0278776.
448 doi:10.1371/journal.pone.0278776
- 449 15. Garcia-Dias R, Scarpazza C, Baecker L, et al. Neuroharmony: A new tool for harmonizing
450 volumetric MRI data from unseen scanners. *Neuroimage*. Oct 15 2020;220:117127.
451 doi:10.1016/j.neuroimage.2020.117127
- 452 16. van der Flier WM, Pijnenburg YA, Prins N, et al. Optimizing patient care and research: the
453 Amsterdam Dementia Cohort. *J Alzheimers Dis*. 2014;41(1):313-27. doi:10.3233/JAD-132306
- 454 17. Jack CR, Jr., Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative
455 (ADNI): MRI methods. *J Magn Reson Imaging*. Apr 2008;27(4):685-91. doi:10.1002/jmri.21049

- 456 18. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study
457 of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal
458 study of Alzheimer's disease. *Int Psychogeriatr*. Aug 2009;21(4):672-87.
459 doi:10.1017/S1041610209009405
- 460 19. Frisoni GB, Prestia A, Zanetti O, et al. Markers of Alzheimer's disease in a population
461 attending a memory clinic. *Alzheimers Dement*. Jul 2009;5(4):307-17.
462 doi:10.1016/j.jalz.2009.04.1235
- 463 20. Brueggen K, Grothe MJ, Dyrba M, et al. The European DTI Study on Dementia - A multicenter
464 DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. *Neuroimage*. Jan
465 2017;144(Pt B):305-308. doi:10.1016/j.neuroimage.2016.03.067
- 466 21. Bankó ÉM, Weiss B, Hevesi I, et al. Study protocol of the Hungarian Longitudinal Study of
467 Healthy Brain Aging (HuBA). *medRxiv*. 2023:2023.11.09.23298159.
468 doi:10.1101/2023.11.09.23298159
- 469 22. Cavedo E, Redolfi A, Angeloni F, et al. The Italian Alzheimer's Disease Neuroimaging Initiative
470 (I-ADNI): validation of structural MR imaging. *J Alzheimers Dis*. 2014;40(4):941-52. doi:10.3233/JAD-
471 132666
- 472 23. Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC)
473 database: the Uniform Data Set. *Alzheimer Dis Assoc Disord*. Jul-Sep 2007;21(3):249-58.
474 doi:10.1097/WAD.0b013e318142774e
- 475 24. Marcus DS, Wang TH, Parker J, Csernansky JG, Morris JC, Buckner RL. Open Access Series of
476 Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and
477 demented older adults. *J Cogn Neurosci*. Sep 2007;19(9):1498-507. doi:10.1162/jocn.2007.19.9.1498
- 478 25. Galluzzi S, Marizzoni M, Babiloni C, et al. Clinical and biomarker profiling of prodromal
479 Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a
480 'European ADNI study'. *J Intern Med*. Jun 2016;279(6):576-91. doi:10.1111/joim.12482
- 481 26. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the
482 causes of a wide range of complex diseases of middle and old age. *PLoS Med*. Mar
483 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 484 27. Gorgolewski KJ, Auer T, Calhoun VD, et al. The brain imaging data structure, a format for
485 organizing and describing outputs of neuroimaging experiments. *Sci Data*. Jun 21 2016;3:160044.
486 doi:10.1038/sdata.2016.44
- 487 28. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of
488 neuroanatomical structures in the human brain. *Neuron*. Jan 31 2002;33(3):341-55.
489 doi:10.1016/s0896-6273(02)00569-x
- 490 29. Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC: Advancing
491 the automatic prediction of image quality in MRI from unseen sites. *PLoS One*. 2017;12(9):e0184661.
492 doi:10.1371/journal.pone.0184661
- 493 30. Monereo-Sanchez J, de Jong JJA, Drenthen GS, et al. Quality control strategies for brain MRI
494 segmentation and parcellation: Practical approaches and recommendations - insights from the
495 Maastricht study. *Neuroimage*. Aug 15 2021;237:118174. doi:10.1016/j.neuroimage.2021.118174
- 496 31. Matelsky J, Kiar G, Johnson E, Rivera C, Toma M, Gray-Roncal W. Container-Based Clinical
497 Solutions for Portable and Reproducible Image Analysis. *J Digit Imaging*. Jun 2018;31(3):315-320.
498 doi:10.1007/s10278-018-0089-4
- 499 32. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: Synthetic minority over-sampling
500 technique. *J Artif Intell Res*. 2002;16:321-357. doi:DOI 10.1613/jair.953
- 501 33. Chen H, Young A, Oxtoby NP, Barkhof F, Alexander DC, Altmann A, investigators A.
502 Transferability of Alzheimer's disease progression subtypes to an independent population cohort.
503 *Neuroimage*. May 1 2023;271:120005. doi:10.1016/j.neuroimage.2023.120005
- 504 34. Adams HHH, Evans TE, Terzikhan N. The Uncovering Neurodegenerative Insights Through
505 Ethnic Diversity consortium. *Lancet Neurol*. Oct 2019;18(10):915. doi:10.1016/S1474-
506 4422(19)30324-2

507 35. Bron EE, Klein S, Papma JM, et al. Cross-cohort generalizability of deep and conventional
508 machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. *Neuroimage Clin.*
509 2021;31:102712. doi:10.1016/j.nicl.2021.102712
510

511 **Figures and Tables**

Manufacturer	Scanner Model	Magnetic Field (T)	Number of scans (Female %)
Canon	Titan	3.0	581 (43.4%)
GE	Discovery MR750	3.0	662 (43.8%)
	Discovery MR750w	3.0	24 (33.3%)
	Genesis Signa	1.5	9 (66.7%)
	Signa Excite	1.5	378 (47.8%)
	Signa PET/MR	3.0	31 (48.3%)
	Signa HDx	1.5	29 (34.5%)
	Signa HDx	3.0	99 (44.4%)
	Signa HDxt	1.5	486 (46.3%)
	Signa HDxt	3.0	998 (46.4%)
	Signa Premier	3.0	14 (42.9%)
Philips	Achieva	1.5	11 (36.3%)
	Achieva	3.0	295 (60.6%)
	Achieva dStream	3.0	23 (56.5%)
	Eclipse	1.5	41 (68.3%)
	Gemini	3.0	526 (59.3%)
	Gyroscan NT	1.0	195 (65.1%)
	Ingenia	3.0	51 (35.3%)
	Ingenuity	3.0	637 (46.7%)
	Intera	1.0	436 (63.1%)
	Intera	1.5	61 (31.1%)
	Intera	3.0	54 (50.0%)
	Intera Achieva	1.5	5 (20.0%)
	Intera Gyroscan	1.5	27 (40.7%)
Siemens	Allegra	3.0	84 (59.5%)
	Avanto	1.5	303 (49.5%)
	Biograph	3.0	5 (0.0%)
	Espreo	1.5	7 (42.8%)
	Magnetom Expert	1.0	813 (48.8%)
	Magnetom Impact	1.0	9 (77.8%)


	Magnetom Vida	3.0	20 (30.0%)
	Magnetom Vision	1.5	27 (74.1%)
	Prisma	3.0	253 (51.8%)
	Prima fit	3.0	216 (56.5%)
	RCNS	3.0	116 (58.6%)
	Skyra	3.0	11181 (54.9%)
	Sonata	1.5	415 (45.5%)
	Sonata Vision	1.5	5 (60%)
	Symphony	1.5	156 (57.7%)
	Trio	3.0	62 (66.2%)
	Trio Tim	3.0	837 (54.6%)
	Verio	3.0	323 (57.6%)
	Vision	1.5	359 (64.9%)

512 **Table 1:** Scanners considered in this study and their characteristics.

513

	Participants (processed/ considered after removing outliers)	Age [years] [†]	Sex (F/M) [†]	Diagnosis (CN / SCD / MCI / AD) [†]	Unique scanners [†]
ADC	4,086 / 3,722	63.9 ± 9.2	1,717 / 2,005	0 / 1,355 / 805 / 1562	12
ADNI	2,044 / 1,830	72.2 ± 7.06	889 / 941	687 / 0 / 851 / 292	27
AIBL	557 / 524	72.7 ± 6.5	299 / 225	388 / 0 / 83 / 53	3
ARWiBo	913 / 831	56.3 ± 16.2	529 / 302	603 / 16 / 116 / 96	7
EDSD	416 / 384	70.4 ± 7.3	197 / 187	143 / 0 / 119 / 122	8
HuBA	121 / 116	62.4 ± 6.9	68 / 48	116 / 0 / 0 / 0	1
I-ADNI	179 / 172	72.2 ± 8.0	106 / 66	2 / 5 / 35 / 130	4
NACC	1,861 / 1,731	71.9 ± 9.8	910 / 821	0 / 0 / 949 / 782	22
OASIS	373 / 359	73.2 ± 10.7	233 / 126	211 / 0 / 111 / 37	1
PharmaCog	141 / 137	69.0 ± 7.3	80 / 57	0 / 0 / 137 / 0	7
UKBB	12,259 / 11,058	63.5 ± 7.6	6,083 / 4,975	11,058 / 0 / 0 / 0	1
Total	22,950 / 20,864	65.3 ± 9.4	11,111 / 9,753	13,208 / 1,376 / 3,206 / 3,074	43

514 **Table 2:** Participant Demographics. † Values indicated in the column are calculated after removing the outliers, as
515 described in section 2.2. Abbreviations: CN: cognitively normal; SCD: subjective cognitive decline; MCI: mild cognitive
516 impairment; AD: Alzheimer’s Disease.




517

518 **Figure 1:** Diagnosis-wise distributions of age for each scanner in the training cohort. Abbreviations: CN: cognitively normal;

519 SCD: subjective cognitive decline; MCI: mild cognitive impairment; AD: Alzheimer's Disease.

520




521

522 **Figure 2:** Experiment 1: Biomarker concordance for brain volumes on unseen scanners using different harmonization
523 strategies. Concordance for non-harmonized data has also been shown here as a reference measure for comparison.

524 Abbreviations: CN: cognitively normal; SCD: subjective cognitive decline; MCI: mild cognitive impairment; AD: Alzheimer's


525 Disease.



526

527 **Figure 3:** Experiment 1: Boxplots of AUCs for distinguishing CN participants from AD patients in the test set based on the 86
528 brain ROIs considered before and after harmonization. Abbreviations: CN: cognitively normal; AD: Alzheimer's Disease.

529



530

531 **Figure 4:** Experiment 2: Accuracy of harmonization for harmonizing brain volumes on seen versus unseen scanners using
532 normative model and multi-class model. Abbreviations: CN: cognitively normal; SCD: subjective cognitive decline; MCI: mild
533 cognitive impairment; AD: Alzheimer's Disease.

534